NO831223L - Immunoglobulinpreparater for bruk til behandling av kreft - Google Patents

Immunoglobulinpreparater for bruk til behandling av kreft

Info

Publication number
NO831223L
NO831223L NO831223A NO831223A NO831223L NO 831223 L NO831223 L NO 831223L NO 831223 A NO831223 A NO 831223A NO 831223 A NO831223 A NO 831223A NO 831223 L NO831223 L NO 831223L
Authority
NO
Norway
Prior art keywords
host
igg
protein
cancer
plasma
Prior art date
Application number
NO831223A
Other languages
English (en)
Norwegian (no)
Inventor
David Stephen Terman
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of NO831223L publication Critical patent/NO831223L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO831223A 1982-04-07 1983-04-06 Immunoglobulinpreparater for bruk til behandling av kreft NO831223L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36643682A 1982-04-07 1982-04-07
US47236283A 1983-03-11 1983-03-11

Publications (1)

Publication Number Publication Date
NO831223L true NO831223L (no) 1983-10-10

Family

ID=27003359

Family Applications (5)

Application Number Title Priority Date Filing Date
NO831223A NO831223L (no) 1982-04-07 1983-04-06 Immunoglobulinpreparater for bruk til behandling av kreft
NO841498A NO841498L (no) 1982-04-07 1984-04-13 Fremgangsmaate for fremstilling av et zymosan-aktivert preparat for bruk til behandling av kreft
NO841497A NO841497L (no) 1982-04-07 1984-04-13 Fremgangsmaate for fremstilling av et protein a-igg preparat for bruk til behandling av kreft
NO841496A NO841496L (no) 1982-04-07 1984-04-13 Fremgangsmaate for fremstilling av et protein a-igg preparat for bruk ved behandling av kreft
NO841495A NO841495L (no) 1982-04-07 1984-04-13 Fremgangsmaate for fremstilling av immunoglobulinpreparater for bruk til behandling av kreft

Family Applications After (4)

Application Number Title Priority Date Filing Date
NO841498A NO841498L (no) 1982-04-07 1984-04-13 Fremgangsmaate for fremstilling av et zymosan-aktivert preparat for bruk til behandling av kreft
NO841497A NO841497L (no) 1982-04-07 1984-04-13 Fremgangsmaate for fremstilling av et protein a-igg preparat for bruk til behandling av kreft
NO841496A NO841496L (no) 1982-04-07 1984-04-13 Fremgangsmaate for fremstilling av et protein a-igg preparat for bruk ved behandling av kreft
NO841495A NO841495L (no) 1982-04-07 1984-04-13 Fremgangsmaate for fremstilling av immunoglobulinpreparater for bruk til behandling av kreft

Country Status (13)

Country Link
EP (1) EP0091784B1 (en:Method)
AU (2) AU569467B2 (en:Method)
CA (1) CA1230555A (en:Method)
DE (1) DE3374756D1 (en:Method)
DK (1) DK154283A (en:Method)
ES (5) ES8405621A1 (en:Method)
FI (1) FI831169L (en:Method)
GB (2) GB2119803B (en:Method)
GR (1) GR78514B (en:Method)
NO (5) NO831223L (en:Method)
PT (1) PT76505B (en:Method)
RO (3) RO89496A (en:Method)
ZW (1) ZW7583A1 (en:Method)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2161813B (en) * 1984-07-20 1988-07-13 Michiko Koga Anti-tumor agent
GB9013872D0 (en) * 1990-06-21 1990-08-15 Inst Tecnologico Y Cientifico Use of protein a and polypeptide components thereof in the treatment of tumours
WO1994024275A1 (en) * 1993-04-08 1994-10-27 Board Of Regents, The University Of Texas System Model for gonococcal infection
GB2422311A (en) * 2005-01-20 2006-07-26 Martin Lister Treatment of blood to cure disease
DE102005012594A1 (de) 2005-03-18 2006-09-21 Bayer Technology Services Gmbh Elektrofiltrationsverfahren
JP2012526997A (ja) * 2009-05-14 2012-11-01 オートミール バイオテクノロジーズ グループ， エル．エル．シー． 自発的に生じる疾患のためのプラットフォーム技術
EP3426265B1 (en) * 2016-04-28 2021-09-22 Alkahest, Inc. Plasma fractions as therapy for tumor growth and progression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132769A (en) * 1974-10-30 1979-01-02 Osther Kurt B Cancer antigen, cancer therapy, and cancer diagnosis
US4146603A (en) * 1977-02-18 1979-03-27 Research Corporation Tumor specific glycoproteins and method for detecting tumorigenic cancers
FI791551A7 (fi) * 1978-05-17 1981-01-01 As Alfred Benzon Puhdistettu syöpäassosioitunut proteiini.

Also Published As

Publication number Publication date
NO841495L (no) 1983-10-10
PT76505A (en) 1983-05-01
GB8309348D0 (en) 1983-05-11
NO841497L (no) 1983-10-10
AU1560088A (en) 1988-10-27
DE3374756D1 (en) 1988-01-14
AU569467B2 (en) 1988-02-04
ES8503954A1 (es) 1985-04-16
GB2163164B (en) 1986-09-03
EP0091784A3 (en) 1984-07-11
ES8503950A1 (es) 1985-04-16
ES521279A0 (es) 1984-06-16
ES528119A0 (es) 1985-04-16
GB2119803A (en) 1983-11-23
PT76505B (en) 1986-05-05
RO86661A (ro) 1986-07-30
GR78514B (en:Method) 1984-09-27
DK154283A (da) 1983-10-08
ES8503953A1 (es) 1985-04-16
GB2163164A (en) 1986-02-19
FI831169A7 (fi) 1983-10-08
RO89496A (ro) 1986-06-30
RO86661B (ro) 1985-03-01
RO89498A (ro) 1986-06-30
EP0091784B1 (en) 1987-12-02
ES528118A0 (es) 1985-04-16
ZW7583A1 (en) 1983-06-29
DK154283D0 (da) 1983-04-07
ES528120A0 (es) 1985-04-16
NO841498L (no) 1983-10-10
NO841496L (no) 1983-10-10
GB8510892D0 (en) 1985-06-05
ES8405621A1 (es) 1984-06-16
EP0091784A2 (en) 1983-10-19
FI831169L (fi) 1983-10-08
ES8601703A1 (es) 1985-11-01
GB2119803B (en) 1986-09-03
FI831169A0 (fi) 1983-04-06
AU1286583A (en) 1983-10-13
ES528121A0 (es) 1985-11-01
CA1230555A (en) 1987-12-22

Similar Documents

Publication Publication Date Title
Liso et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma
RU2139092C1 (ru) Фрагменты антител в терапии
JP5950824B2 (ja) 抗腫瘍抗体療法を増強するための方法
US4699783A (en) Products and methods for treatment of cancer
JP2020147574A (ja) 炎症及び自己免疫障害を治療するための抗ａｇｅ抗体
JPH05504554A (ja) 免疫強化を促進するための方法と組成物
EP0805871A1 (en) Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
RU2517084C2 (ru) Способ и средство для ингибирования продукции или усиления элиминации белка р24
NO831223L (no) Immunoglobulinpreparater for bruk til behandling av kreft
CZ20013270A3 (cs) Protilátkové a chemokinové konstrukty a jejich pouľití při léčbě autoimunitních chorob
Oon et al. Clinical applications of the continuous flow blood separator machine
YAMAZAKI et al. Antibody-dependent macrophage-mediated cytolysis in a murine syngeneic tumor system
Assmann et al. Comparison of antigenic targets involved in antibody-mediated membranous glomerulonephritis in the mouse and rat
JPS6053009B2 (ja) 肝炎ウイルスｂによる急性または慢性の感染治療用の新規医薬
US4009257A (en) Preparation of immunosuppressive materials
JPS6127926A (ja) 細胞毒性薬剤組成物及び細胞毒性薬剤キット
JP7016374B2 (ja) 悪性の固形および全身性腫瘍の治療、診断および予防において使用するための安定なポリマー状の新規組換えタンパク質ｕｋ１１４
Cameron et al. Characterization of the preformed antibodies involved in the xenograft reaction
TW202237663A (zh) 抗-t細胞奈米抗體暨其核酸編碼序列及其應用
CA1242392A (en) Products and methods for treatment of cancer
JPS58201717A (ja) 腫瘍免疫製剤およびその製造方法
CA1233748A (en) Products and methods for treatment of cancer
Kumar et al. Autologous Hsp70 immunization induces anti-tumor immunity and increases longevity and survival of tumor-bearing mice
CN120248122B (zh) 一种靶向uPAR的单链抗体、嵌合抗原受体及其应用
Griswold et al. Glomerular localization of antigen and antibody in rabbits following intravenous administration of serum cryoproteins from homologous animals with acute serum sickness